Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 186 HER2-positive Breast Cancer 18 Neoplasm Metastasis 6 Inflammatory Breast Neoplasms 5 Triple Negative Breast Neoplasms 4 Neoplasms 4 Prostatic Neoplasms 3 Pathologic Complete Response 3 Pancreatic Neoplasms 3 HER2-positive Early Breast Cancer 3 Endometrial Neoplasms 3 Breast Neoplasms, Male 3 Anatomic Stage I Breast Cancer AJCC v8 3 Stomach Neoplasms 2 Ovarian Neoplasms 2 Multiple Myeloma 2 Locally Advanced Breast Cancer 2 Hematologic Neoplasms 2 HER2-positive Metastatic Breast Cancer 2 Gastrointestinal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Carcinoma, Ductal, Breast 2 Breast Diseases 2 Brain Neoplasms 2 Anatomic Stage II Breast Cancer AJCC v8 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Thyroid Neoplasms 1 Thrombocytosis 1

Interventions

Trastuzumab 4 pyrotinib 3 Vinorelbine 2 pertuzumab 1 copanlisib 1 Lapatinib 1 Docetaxel 1 Carboplatin 1 Capecitabine 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

HER2 Positive Breast Cancer × pertuzumab × Breast × Clear all

NCT01904903 2022-05-10

SAFE-HEaRt

Medstar Health Research Institute

Phase 2 Completed

31 enrolled 12 charts

HER2 Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡